Percutaneous Coronary Intervention Lowers Risk of Heart Disease

Treating left main coronary artery disease with percutaneous coronary intervention lowers the risk of severe cardiovascular events after weeks of surgery.

Percutaneous coronary intervention can reduce the risk of severe cardiovascular events in treating left main coronary artery disease, reveals a new study.

A meta-analysis of several trials and nearly 5,000 patients revealed no differences in mortality between the two treatments.

Surprising Trends Found in Cause of Long-Term Death After Percutaneous Coronary Intervention
More people with known coronary heart disease die because of other conditions like cancer, lung and neurological diseases, rather than heart disease as compared to 20 years ago, reveals a Mayo Study.

‘Percutaneous coronary intervention is better than coronary artery bypass grafting in reducing the risk of severe cardiovascular events.’

The finding is significant when it comes to selecting the form of treatment: percutaneous coronary intervention is less burdensome on the patient, as it does not require long-term hospitalisation and enables rapid return to work.

The prognosis of left main coronary artery disease is worse than in any other form of coronary artery disease. The treatment options include percutaneous coronary intervention and coronary artery bypass grafting.

In European and American treatment guidelines, coronary artery bypass grafting is generally regarded as the first-line treatment for severe left main coronary artery disease. However, some studies have suggested that percutaneous coronary intervention with drug-releasing stent implantation would also be a recommendable course of treatment in the severe form of the disease, but the evidence has been inconsistent.

Systolic Blood Pressure is a Useful Predictor for Patients Experiencing STEMI
STEMI is one type of myocardial infarction in which a part the heart muscle (myocardium) has died due to the obstruction of blood supply to the area.

A new study by investigators from the University of Eastern Finland and Oulu University Hospital compared percutaneous coronary intervention with drug-releasing stent implantation and coronary artery bypass grafting in the treatment of left main coronary artery disease.

The authors pooled evidence from six comparable, randomised, controlled trials involving 4,700 people.

Aspirin may Influence Heart Problems After Normal Surgery
Previous stent or angioplasty patients can experience heart problems after a normal surgery with peri-operative aspirin therapy

The researchers analysed all available randomized studies among patients who had undergone percutaneous coronary intervention or coronary artery bypass grafting, comparing their risk of all-cause mortality, major adverse cardiac and cerebrovascular events, and other cardiovascular events at time points of 30 days, one year and three years after surgery.

There were no differences between the treatments as regards the risk of death, or cardiac or cerebrovascular events. Percutaneous coronary intervention patients needed repetitive interventions more often over the years.

New ESC Guidelines Help Treat STEMI Patients
New guidelines published provide a clear definition of when to start the clock for the 90 minute target to treat patients with percutaneous coronary intervention (PCI).

According to the researchers, the findings suggest that percutaneous coronary intervention with drug-releasing stent implantation should be more frequently considered as a treatment option for patients suffering from left main coronary artery disease.

There are no differences in mortality between patients of percutaneous coronary intervention and patients undergoing coronary artery bypass grafting, and as percutaneous coronary intervention is less burdensome on the patient both from the viewpoint of quality of life and functional capacity, it is an option worth considering.

Source-Eurekalert